Voluntary recall – Zerbaxa® (ceftolozane/tazobactam) due to manufacturing issue

A Dear Healthcare Professional Letter has been issued by MSD Pharma (Singapore) to inform healthcare professionals of the recall of Zerbaxa® for injection (1.5 g) 1g/0.5g 10×20ml vial. Due to a recent routine testing, the results of sterility tests of seven batches of product were out of specification. These seven batches have not been released into the market. While these products distributed to the market had met the registered release specifications, they were manufactured on the same equipment as the affected batches. As a result, MSD is conducting a voluntary recall of all Zerbaxa® injections within expiry. Healthcare professionals are advised to discontinue the use of Zerbaxa® and consider alternative treatment plans for their patients. Please refer to the letter for details.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

28 Dec 2020

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.